Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 6/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4634711 | 0.89 | ENPP2 (0.55) | ENPP2KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4634714 | 0.86 | POLB (0.52) | ENPP2KMT2AKDM4ERAB9AALDH1A1 | |
| SCHEMBL4634615 | 0.86 | SMN1; SMN2 (0.46) | ENPP2KDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL4634108 | 0.85 | ENPP2 (0.44) | ENPP2KMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4634824 | 0.84 | MDH1 (0.48) | ENPP2KMT2AALDH1A1SMN1; SMN2FKBP1A | |
| SCHEMBL4635527 | 0.81 | FKBP1A (0.44) | ENPP2KMT2AKDM4ERAB9AALDH1A1 | |
| SCHEMBL4635164 | 0.78 | ALDH1A1 (0.47) | KMT2AALDH1A1SMN1; SMN2FKBP1AMEN1 | |
| SCHEMBL4635611 | 0.78 | CYP3A4 (0.44) | ENPP2KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL4634118 | 0.77 | NPC1 (0.43) | KMT2AKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL4635888 | 0.77 | CYP3A4 (0.46) | KMT2AKDM4ENPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928829-A1 | PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Schering Aktiengesellschaft (DE) | 2008-06-11 | — | — | EP | claimed |
| US-20060167044-A1 | Piperidine derivatives and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-27 | — | — | US | claimed |
| WO-2006066948-A1 | PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | claimed |
| EP-1928829-A1 | PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Schering Aktiengesellschaft (DE) | 2008-06-11 | — | — | EP | disclosed |
| US-20060167044-A1 | Piperidine derivatives and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-27 | — | — | US | disclosed |
| WO-2006066948-A1 | PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167044-A1 | Piperidine derivatives and their use as anti-inflammatory agents | CCR1, CCR2, CCR3 | ENPP2 1944/4885KMT2A 4584/4885KDM4E 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.